CT18 Infant Influenza Priming Study in Vaccine Naive Infants

Children under 24 months of age suffer from an influenza burden (high morbidity and mortality) similar to that of the elderly, and have been identified as a high priority target for vaccination programs by Canada's National Advisory Committee on Immunization. There is evidence that a person's first exposure to influenza antigens may have long‐term implications for protection. This is a randomized, controlled, observer‐blind study that will assign participants to one of three groups. Group 1 will receive MF59‐adjuvanted influenza vaccine (two doses one month apart) in the fall of year 1, followed by QIV (one dose) in the fall of year 2. Group 2 will receive QIV (two doses one month apart) in the fall of year 1, followed by QIV (one dose) in the fall of year 2. Group 3 will receive MF59‐adjuvanted IV (two doses one month apart) in the fall of year 1, followed by MF59‐adjuvanted IV (one dose) in the fall of year 2.